Compare ACU & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | ELDN |
|---|---|---|
| Founded | 1867 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 166.4M |
| IPO Year | 1994 | 2014 |
| Metric | ACU | ELDN |
|---|---|---|
| Price | $44.80 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 8.2K | ★ 522.1K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $194,489,991.00 | N/A |
| Revenue This Year | $2.19 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $22.07 | ★ N/A |
| Revenue Growth | ★ 1.56 | N/A |
| 52 Week Low | $35.31 | $1.35 |
| 52 Week High | $45.60 | $4.60 |
| Indicator | ACU | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 53.60 |
| Support Level | $42.98 | $2.08 |
| Resistance Level | $45.20 | $2.21 |
| Average True Range (ATR) | 1.17 | 0.15 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 58.22 | 46.67 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.